OncoImmunology · 2013 · 26 citations · 25 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunoregulationImmunotherapyAntigen RecognitionAntitumor T Cell ResponsesCancer ImmunotherapyRegulatory T CellsTumor AntigensTumor-associated AntigensCd4 Positive T CellsEffector Memory T CellsHla Class Ii MoleculesHla Class Ii RestrictionPeripheral Regulatory T CellsT-cell Responses To Tumor AntigensTumor Antigen RecognitionTumor-associated Antigen Recognition
Regulatory T cells (Tregs) play an important role in controlling antitumor T-cell responses and hence represent a considerable obstacle for cancer immunotherapy. The abundance of specific Treg populations in cancer patients has been poorly analyzed so far. Here, we demonstrate that in breast cancer patients, Tregs often control spontaneous effector memory T-cell responses against mammaglobin, a common breast tissue-associated antigen that is overexpressed by breast carcinoma. Using functional assays, we identified a HLA-DRB1*04:01- and HLA-DRB1*07:01-restricted epitope of mammaglobin (mam34–48) that was frequently recognized by Tregs isolated from breast cancer patients. Using mam34–48-labeled HLA Class II tetramers, we quantified mammaglobin-specific Tregs and CD4+ conventional T (Tcon) cells in breast carcinoma patients as well as in healthy individuals. Both mammaglobin-specific Tregs and Tcon cells were expanded in breast cancer patients, each constituting approximately 0.2% of their respective cell subpopulations. Conversely, mammaglobin-specific Tregs and CD4+ Tcon cells were rare in healthy individuals (0.07%). Thus, we provide here for the first time evidence supporting the expansion of breast tissue-specific Tregs and CD4+ Tcon cells in breast cancer patients. In addition, we substantiate the potential implications of breast tissue-specific Tregs in the suppression of antitumor immune responses in breast cancer patients. The HLA Class II tetramers used in this study may constitute a valuable tool to elucidate the role of antigen-specific Tregs in breast cancer immunity and to monitor breast cancer-specific CD4+ T cells.
25
Tumor-Infiltrating CD8<sup>+</sup>Lymphocytes Predict Clinical Outcome in Breast Cancer
Sahar Mahmoud, Emma C. Paish, Desmond G. Powe et al. · Journal of Clinical Oncology · 2011 · 1.4K citations · Full text
Life Sciences, Immunology, Oncology +17
The Central Role of CD4+ T Cells in the Antitumor Immune Response
Kenneth E. Hung, Robert J. Hayashi, Anne Lafond-Walker et al. · The Journal of Experimental Medicine · 1998 · 1.3K citations · Full text
Life Sciences, Immunology, Oncology +17
Ruka Setoguchi, Shohei Hori, Takeshi Takahashi et al. · The Journal of Experimental Medicine · 2005 · 1.2K citations · Full text